Document Detail


The risk of recurrent venous thromboembolism.
MedLine Citation:
PMID:  12236019     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Venous thromboembolism (VTE) is a chronic rather than acute disease. After withdrawal of secondary thromboprophylaxis, many patients will experience a subsequent episode of thrombosis. Of these patients, approximately 5% will die from pulmonary embolism. The risk of recurrent VTE depends on the number of risk factors and their severity. High-risk patients, i.e. those with a natural coagulation inhibitor deficiency, recurrent thrombosis, active cancer, the lupus anticoagulant or compound clotting defects most probably benefit from indefinite oral anticoagulation. In these patients the risk of bleeding due to anticoagulant treatment seems to be outweighed by the risk of VTE. Patients with hyperhomocysteinemia or high factor (F) VIII plasma levels are also at an increased risk of recurrence. The optimal duration of secondary thromboprophylaxis in these patients is currently under investigation. Patients with the heterozygous F V Leiden mutation or the G20210A mutation in the F II gene do not require extended anticoagulation since their risk of recurrence is similar as in patients without the aforementioned mutations. Patients with VTE secondary to surgery or trauma have a relatively low risk of recurrence. In these patients short-term secondary thromboprophylaxis (6 to 12 weeks) is justified whereas patients with a first episode of spontaneous VTE should be treated with oral anticoagulants for a longer period of time (3 to 6 months).
Authors:
P A Kyrle; S Eichinger
Related Documents :
12686699 - An association between atherosclerosis and venous thrombosis.
12522659 - Thrombosis in children with cardiac pathology: frequency of factor v leiden and prothro...
686259 - Position artifacts in occlusive impedance phlebography (plethysmography).
9716579 - Heparin-induced thrombocytopenia: new insights into the impact of the fcgammariia-r-h13...
1286989 - Analysis of venous access for therapeutic plasma exchange in patients with neurological...
7831679 - Prothrombin fragment f 1 + 2 and oral anticoagulant therapy.
23525999 - Objective evaluation of velopharyngeal function by acoustic reflection measurements.
2011159 - Dysphagia in patients with the post-polio syndrome.
3457709 - Elevated serum concentrations of ca-125 in patients with advanced endometriosis.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  VASA. Zeitschrift für Gefässkrankheiten     Volume:  31     ISSN:  0301-1526     ISO Abbreviation:  VASA     Publication Date:  2002 Aug 
Date Detail:
Created Date:  2002-09-18     Completed Date:  2002-12-04     Revised Date:  2012-10-19    
Medline Journal Info:
Nlm Unique ID:  0317051     Medline TA:  Vasa     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  163-6     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine I, Division of Hematology and Hemostasis, Ludwig Boltzmann Institute for Thrombosis Research, Vienna University Hospital, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Anticoagulants / administration & dosage,  adverse effects
Humans
Long-Term Care
Pulmonary Embolism / drug therapy,  etiology*
Recurrence
Risk Factors
Venous Thrombosis / drug therapy,  etiology*
Chemical
Reg. No./Substance:
0/Anticoagulants

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  [Current status of endovascular therapy in the femoropopliteal vascular segment in chronic periphera...
Next Document:  [Endovascular therapy of aneurysms of the abdominal aorta: report of 4,291 patients of the Eurostar ...